Metagenomi TherapeuticsMGX +0.79%10 PB Ratio is 0.35 as of Jul. 13, 2026, which is 5% below its 10-year median of 0.37. GuruFocus rates MGX with a GF Score™ of 10/100. The stock has 4 warning signs investors should review. Among 1,231 Biotechnology companies, Metagenomi Therapeutics ranks better than 96.59% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Metagenomi Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Metagenomi Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Metagenomi Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Metagenomi Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Metagenomi Therapeutics (MGX) has a PB Ratio of 0.35 as of Jul. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Metagenomi Therapeutics and its competitors. This is near median its historical median of 0.37. Over the past decade, Metagenomi Therapeutics' PB Ratio has ranged from 0.24 to 1.34. According to the industry distribution chart, Metagenomi Therapeutics ranks #42 out of 1231 companies in the Biotechnology industry, placing it in the top 3.4%.
Is Metagenomi Therapeutics' PB Ratio too high?
Metagenomi Therapeutics' current PB Ratio of 0.35 is near median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 1.34. The Biotechnology industry median PB Ratio is 2.93. Metagenomi Therapeutics' value of 0.35 is 88.1% below this industry median. Based on the distribution chart, Metagenomi Therapeutics ranks #42 out of 1231 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Metagenomi Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Metagenomi Therapeutics' PB Ratio compare to KALA and HYPD?
According to the Biotechnology industry distribution chart, Metagenomi Therapeutics ranks #42 out of 1231 companies for PB Ratio. This places Metagenomi Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.93. Metagenomi Therapeutics' value of 0.35 is 88.1% below this benchmark. Historically, Metagenomi Therapeutics' own PB Ratio has ranged from 0.24 to 1.34 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 2.93, Metagenomi Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.93, based on 1,231 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Metagenomi Therapeutics's current PB Ratio of 0.35 is 88.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Metagenomi Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Metagenomi Therapeutics's current PB Ratio is 0.35, which is near median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Metagenomi Therapeutics stock overvalued right now?
Metagenomi Therapeutics (MGX) has a current PB Ratio of 0.35. The current PB Ratio is 0.35, which is near median its 10-year median of 0.37 and 88.1% below the Biotechnology industry median of 2.93. Metagenomi Therapeutics' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Metagenomi Therapeutics (MGX), the current PB Ratio is 0.35 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Metagenomi Therapeutics Inc is an vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. The company leverages machine learning and artificial intelligence to enhance its signature gene editing systems. MGX-001 is its, wholly-owned development program in hemophilia A, where the company have demonstrated targeted genome editing and durable gene expression from a one-time treatment in non-human primates (NHPs) and an overall profile potentially competitive with best-in-class treatment options. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A from a single administration.
10GF Score
Get the complete analysis for MGX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MGX has been successfully added to your 
